BRAF and melanoma: The landscape of melanoma therapy has changed dramatically within the last few years with the discovery that the majority of melanomas harbor activating mutations in BRAF[1], [2] and that virtually all melanomas exhibit constitutive activity in the MAP kinase pathway [3].